Posted inHematology-Oncology news
AlloHSCT in Adult Ph– ALL Treated with Pediatric-Inspired GIMEMA LAL1913: MRD Status at Transplant Drives Long-Term Outcomes
Campus ALL real-world data show that pre-transplant MRD negativity after the pediatric-inspired GIMEMA LAL1913 protocol predicts substantially better 3‑year OS and DFS after alloHSCT; MRD-positive patients and those in CR2 fare markedly worse, while age >55 years does not preclude benefit.